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Abstract
Thymosin α1 (Tα1) and Bursopentin (BP5) are both immunopotentiators. To explore
whether the thymosin α1-Bursopentin (rTα1-BP5) is an adjuvant or not, we cloned the
gene of Tα1-BP5 and provided evidence that the gene of Tα1-BP5 in a recombinant
prokaryotic expression plasmid was successfully expressed in Escherichia coli BL21. To
evaluate the immune adjuvant properties of rTα1-BP5, chickens were immunized with
rTα1-BP5 combined with H9N2 avian influenza whole-inactivated virus (WIV). The
titers of HI antibody, antigen-specific antibodies, Avian influenza virus (AIV)-neutral-
izing antibodies, levels of Th1-type cytokines (gamma interferon (IFN-γ)) and Th2-type
cytokines (interleukin 4 (IL-4)), and lymphocyte proliferation responses were deter-
mined. We found that rTα1-BP5 enhanced HI antibody and antigen-specific immuno-
globulin G (IgG) antibodies titers, increased the level of AIV-neutralizing antibodies,
induced the secretion of Th1- and Th2-type cytokines, and promoted the proliferation
of  T  and B lymphocyte.  Furthermore,  virus  challenge experiments  confirmed that
rTα1-BP5 contributed to the inhibition replication of the virus (H9N2 AIV (A/chicken/
Jiangsu/NJ07/05) from chicken lungs. Altogether, these findings suggest that rTα1-BP5
is a novel adjuvant suitable for H9N2 avian influenza vaccine.
Keywords: thymosin α1 (Tα1), Bursopentin (BP5), fusion peptide, avian influenza
vaccine, adjuvant
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1. Introduction
Avian influenza virus (AIV) is an enveloped virus that belongs to the Orthomyxoviridae family
and  has  an  eight-segmented,  single-stranded,  negative-sense  RNA  genome.  Among  the
proteins encoded by the genome, there are two surface glycoproteins, hemagglutinin (HA)
and neuraminidase (NA) [1]. AIVs are classified into subtypes according to the combination
of 16 HA and nine NA molecules. Among the many subtypes of AIV, H9N2 is thought to have
originated from shorebirds and gulls, and has rapidly spread to become one of the most
prevalent diseases in domestic poultry worldwide. It also causes serious economic loss in the
poultry industry [2] (see Table 1).
Abbreviation Full name
Tα1 Thymosin α1
BP5 Bursopentin
rTα1-BP5 Thymosin α1-Bursopentin
WIV Whole-inactivated virus
AIV Avian influenza virus
HA Hemagglutinin
NA Neuraminidase
BRM Biological response modifier
MIF Macrophage migration inhibitory factor
BF Bursa of Fabricius
BLP Bursin-like epitope peptide
HI Hemagglutination inhibition assay
IFN-γ Interferon-γ
IL-4 Interleukin-4
TNF-α Tumor necrosis factor-α
Th T-helper type
Th1 T-helper type 1
Th2 T-helper type 2
MDCK Madin-Darby canine kidney
FBS Fetal bovine serum
MTT 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide
IPTG Isopropyl-β-d-thiogalactoside
ConA Concanavalin A
PMA Phorbol-12-myristate-13-acetate
Steps Forwards in Diagnosing and Controlling Influenza120
Abbreviation Full name
TMB Tetramethyl benzidine
HRP Horseradish peroxidase
SPF Specific pathogen-free
SOE-PCR Splicing overlap extension PCR method
TRX Thioredoxin
TCID50 50% tissue culture infective dose
PBS phosphate-buffered saline
pfu Plaque-forming unit
OD Optical density
IgG Immunoglobulin G
ELISA Enzyme-linked immunosorbent assay
PRNT50 50% plaque-reducing neutralizing titer
Table 1. Abbreviations for full name.
In domestic avian species in North America, H9N2 influenza viruses occur primarily in
turkeys, occasionally in quail, and rarely if ever in chickens. The H9N2 virus subtype was first
isolated from turkeys in 1966 [3], when the virus was associated with mild respiratory disease.
In Asia, long-term surveillance in live poultry markets in Hong Kong from 1975 to 1985
detected H9N2 influenza viruses in apparently healthy ducks but not in chickens [4]. Since the
early 1990s, H9N2 influenza viruses have become widespread in domestic chickens in Asia [5].
Among the avian influenza A virus subtypes, H9N2 viruses have the potential to cause an
influenza pandemic because they are widely prevalent in avian species in Asia and have
demonstrated the ability to infect humans [6]. In April 1999, two World Health Organization
reference laboratories independently confirmed the isolation of avian influenza A (H9N2)
viruses for the first time in humans [7].
The best protection against influenza virus infection remains effective vaccination [8]. Inacti-
vated vaccines have been undergoing clinical trials as pandemic vaccine candidates, and it has
been shown that inactivated vaccines elicit strong humoral responses; however, it is commonly
accepted that no adequate mucosal or cellular immunity is achieved [9]. Adjuvants are able to
improve the quantity and quality of innate immune responses by enhancing their speed and
duration, and by inducing adequate adaptive immunity [10]. To improve methods for
influenza vaccine production, the current strategy of many investigators is to increase the
efficacy of pandemic influenza vaccines by the addition of adjuvants to boost immune
responses, such as aluminum salts, MF59, IC31®, and chitosan [11–14].
A defined peptide sequence able to stimulate specific immune cell subsets has the potential to
act as an adjuvant for a variety of immunogens. The thymus is an important central immune
organ for T-lymphocyte differentiation and maturation [15]. It is capable of secreting many
peptides with the functions of regulating the development of different phenotypic markers
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and lymphocyte [16]. Thymosin alpha 1 (Tα1), an immunomodulatory peptide consisting of
28 amino acid residues, was isolated originally from calf thymus [17]. As a biological response
modifier (BRM), Tα1 has multiple biological activities in the immune system. It can promote
specific lymphocyte functions, stimulate the production of lymphokines such as gamma
interferon (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin 2 (IL-2), macrophage migra-
tion inhibitory factor (MIF), and precursor stem cell into the CD4+/CD8+ T cells, increase T-
cell proliferation, differentiation and maturation, and so on [18, 19]. Furthermore, it has the
activities of antitumor and protection against oxidative damage [20]. Consequently, Tα1 is
widely used in clinic treating various diseases including immunodeficiency diseases, severe
sepsis, and systemic infectious disorder [21].
The bursa of Fabricius (BF) is a primary humoral immune organ unique to birds and is the site
of B-lymphocyte development and differentiation. The tripeptidebursin (LysHisGlyNH2) has
been described as an endogenous B-cell stimulant or differentiation factor [22]. BS and bursin-
like peptide T-X-N-L-K-H-G significantly enhance the JEV subtype vaccine-induced immune
response in immunized mice [23]. Bursin-like epitope peptide (BLP) is one of bursin-like
peptides and enhances immune responses in mice immunized with inactivated H9N2 avian
influenza vaccine [24]. Our previous study has been reported that Bursopentin (BP5) is a small
peptide separated from BF, which amino acid sequence is CKDVY. We found that BP5 not only
promotes T-cell and B-cell proliferation, enhances humoral immunity and cellular immunity
but also balances Th1 and Th2 immune responses [25, 26].
Although both Tα1 and BP5 have the potent adjuvant effects, this study designed and
synthesized Tα1-BP5 fusion gene according to the preferential codons of Escherichia coli, fused
with prokaryotic expression vector pET-32a, and then transferred into E. coli BL21 to induce
its expression. Then, we tested whether rTα1-BP5 could enhance immune responses in chicken
upon vaccination with H9N2 avian influenza whole-inactivated virus (WIV).
2. Materials and methods
2.1. Plasmid, viruses, and reagents
pET-32a (+), E. coli DH5α, E. coli BL21 (DE3), pET32a (+)-BP5, and avian influenza virus A/
Chicken/Jiangsu/JS-1/2002(H9N2) were maintained in our laboratory. Avian influenza virus
A/Chicken/Jiangsu/NJ08/05(H9N2) was kindly provided by Dr. Qi-Sheng Zheng. Virus titers
were determined in MDCK cells. H9N2 avian influenza whole-inactivated virus (WIV) was
prepared by diluting the virus 1:4000 (v/v) in formalin [27, 28]. All restriction enzymes and Taq
polymerase were purchased from TakaRa Biotechnology (Dalian, China). RPMI 1640 medium
and fetal bovine serum (FBS) were purchased from Gibco (New York, NY, USA). Isopropyl-β-
d-thiogalactoside (IPTG), 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide
(MTT), TEMED, dNTP, Concanavalin A (ConA), Phorbol-12-myristate-13-acetate (PMA), and
tetramethylbenzidine (TMB) were purchased from Jiu Shi Corporation (Zhengzhou, China).
Horseradish peroxidase (HRP)-conjugated goat anti-mice IgG was obtained from Boshide
Corporation (Wuhan, China). Control Standard Tα1 and BP5 peptides were synthesized by
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Shanghai Science Peptide Biological Technology Co., Ltd. (Shanghai, China), and the purity
was over 95%.
2.2. Chicken embryos, animals, and vaccines
Specific pathogen-free (SPF) Roman chicken and chicken embryos were obtained from the
Henan Experimental Animal Research Center. Avian influenza virus A/Chicken/Jiangsu/
NJ08/05(H9N2) (107 TCID50/0.1 mL) was inoculated into the allantoic cavities of 10-day-old SPF
chicken embryos; the embryos that died within 24 h were discarded, and the allantoic fluids
were harvested from the infected embryos at 48 h postinfection and inactivated by treatment
with 0.2% formalin. The inactivated virus was emulsified with mineral oil to make an oil-
formulated inactivated H9N2 AIV vaccine. One dose of the vaccine contained 107 TCID50/0.1
mL, which was equal to it before inactivation. Procedure and test of inactivated vaccine were
described according to OIE Terrestrial Manual 2012 [29].
2.3. Gene cloning and expression of the recombinant fusion peptide Tα1-BP5
Gene of the recombinant fusion peptide thymosin α1-Bursopentin (Tα1-BP5) was designed
according to the preferential codons of E. coli and amplified by splicing overlap extension
polymerase chain reaction (SOE-PCR) method [30]. Sequences of the primers used for the
synthetic Tα1-BP5 are as follows: F1: 5′-CCG GAA TTC AGC GAC GCT GCT GTT GAC ACT
AGC AGC GAA ATC ACT ACTA AAG ACT TG-3′; F2: 5′-GTT CGG GGT GCTG CCG CCG
CCG CCG TTT TCA GCT TCT TCA ACA ACT TCT TTT TTT TCT TTC AAG TCT TTA GTA
GT-3′; and F3: 5′-GGC GGC GGC GGC AGC TGC AAA AAT GTG TAT TAA GTC GAC
TCG-3′, with EcoR I and SaI I site (underlined). The genes of Tα1 and BP5 were connected with
the gene of the GGGGS linker to form the Tα1-BP5 fusion gene. And then, the amplified DNA
fragment was digested by EcoR I and SaI I, and then ligated into the expression vector pET32a.
The ligation mix was transformed into competent DH5α cells and the single bacterial colony
was selected by overnight growth on Luria broth (LB) agar plates containing 100-μg/mL
ampicillin. The obtained recombinant plasmid pET32a-Tα1-BP5 was confirmed by restriction
endonuclease digestion and DNA sequencing. The pET32a-Tα1-BP5 plasmid was transformed
into E. coli BL21 (DE3) for inducing expression. The expression products were examined by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). And the recombi-
nant proteins were purified on a Ni-affinity chromatography column (Amersham Bioscience
HiTrap chelating HP 5 mL × one column) following the manufacturer’s instructions.
2.4. Activity testing of fusion peptide Tα1-BP5 (rTα1-BP5) in vitro
Thymus and spleens from 4 to 6-week-BALB/c mice with (20 ± 2) g were collected aseptically,
put them at 200-mesh stainless screen mesh cells, and gently minced into single cell suspension
with a syringe followed by adding Hank’s solution. The red blood cells were removed by
centrifugation at 500 rpm for 5 min. The supernatant was centrifuged at 500 rpm for 5 min.
The obtained pellet was washed with Hank’s solution twice. The density of lymphocytes was
adjusted to around 5 × 106 cells/mL using RPMI-1640 medium containing 10% FBS. ConA and
PMA were added into thymic lymphocytes and splenic lymphocytes to make the concentra-
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tions reach 5 μg/mL and 300 ng/mL, respectively. The two kinds of solutions were subpackaged
into a 96-well plate with 100 μL/well, respectively, and three parallel samples were set for each
well. The plates were incubated in CO2 incubator at 37°C for 6 h, followed by adding 100-μL/
well rTα1-BP5 (affinity chromatography purified through Ni column) with different concen-
trations (1.25, 2.5, 5.0, 10.0, and 20.0 μg/mL) and continued culturing for 72 h. Control groups
(phosphate-buffered saline (PBS), 10.0 μg/mL thioredoxin, 10.0 μg/mL Tα1, and 10.0 μg/mL
BP5) were used following the same procedures. MTT method was used to test the effect of
rTα1-BP5 effect on thymic and splenic lymphocytes proliferation. Relative ratio of cell
proliferation (%) = (experimental group OD570/control group OD570) × 100% [31, 32].
2.5. Immunization of chickens
All animal experiments were approved by the Henan University of Science and Technology
Animal Care and Use Committee. Twenty-one-day-old SPF Roman chickens were randomly
divided into six experimental groups of 25 chickens each and intramuscularly immunized two
times on days 0 and 14 with (i) 100 μL PBS as a negative control, (ii) 100 μL H9N2 WIV (A/
Chicken/Jiangsu/NJ08/05, 107 TCID50/0.1 mL), (iii) a mixture of 100 μL H9N2 WIV and Tα1 (50
μg), (iv) a mixture of 100 μL H9N2 WIV and BP5 (50 μg), (v) a mixture of 100 μL H9N2 WIV
and rTα1-BP5 (50 μg), and (vi) 100 μL oil-formulated inactivated H9N2 AIV vaccine (A/
Chicken/Jiangsu/NJ08/05, 107 TCID50/0.1 mL) as a positive control (Table 2).
Group Vaccination on days 0 and 14a
1 100 μL PBS
2 107 TCID50 H9N2 WIV
3 107 TCID50 H9N2 WIV + 50 μg Tα1
4 107 TCID50 H9N2 WIV + 50 μg BP5
5 107 TCID50 H9N2 WIV + 50 μg rTα1-BP5
6 107 TCID50 H9N2 AIV vaccine
a H9N2 WIV, inactivated H9N2 avian influenza whole-inactivated virus; H9N2 AIV vaccine, H9N2 avian influenza
virus vaccine prepared with oil/water as an adjuvant.
Table 2. Animal groups and the experimental design.
The details of the animal experiment time points are shown in Figure 1.
2.6. Detection of antibodies in serum
Chicken (n = 5 per group) sera were collected on 7 and 21 days after the first immunization.
Serum antibody (HI and antigen-specific antibodies) titers were determined using standard
HI microliter and enzyme-linked immunosorbent assay (ELISA) as described [25, 33]. Briefly,
to detect the HI titers in chicken serum, sera were inactivated by incubation for 30 min at 56°C
and serially diluted twofold in PBS, then transferred in duplicate to 96-well round-bottomed
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plates. Standard avian influenza virus (A/Chicken/Shandong/6/96(H9N2)) antigen with four
units was then added to each diluted serum samples in a volume of 50 μL, and followed by
an equal volume of 0.5% chicken erythrocyte suspensions. The mixture was incubated for 1 h
at room temperature before the results were read. The HI titers were defined as the highest
serum dilution capable of preventing hemagglutination.
To evaluate the antigen-specific antibodies titers, ELISA plates were coated with 10-μg/mL
recombinant influenza HA protein (expressed in E. coli BL21) and blocked with 1% bovine
serum albumin (BSA) for 2 h at 37°C. Aliquots of diluted chicken sera were added to the plates,
which were then incubated overnight, washed, and incubated with HRP-conjugated goat anti-
chicken IgG. Finally, TMB was added and the reaction was stopped by the addition of 2N
H2SO4 and the absorbance was read at OD450. Each serum sample was repeated in quintuplicate.
The results were plotted as OD versus dilution (log scale). Titers at half maximal OD were
determined by linear interpolation [34].
2.7. Determination of AIV-neutralizing antibodies
Inactivated sera were incubated with 100 plaque-forming unit (pfu) of avian influenza virus
(A/Chicken/Jiangsu/JS-1/2002(H9N2), and the titers of AIV-neutralizing antibodies deter-
mined as described [35].
2.8. Cytokine assays
On 7 and 21 days after the first immunization, the serum levels of Th1-type cytokine (IFN-γ)
in chickens were determined using commercial Chicken cytokines gamma interferon ELISA
kits (Cusabio Biotech, MD, USA), whereas Th2-type cytokine (IL-4) was determined with
another commercial Chicken cytokines interleukin 4 ELISA kits (Cusabio Biotech, USA). The
procedure followed the manufacturer’s instructions.
Figure 1. Experimental scheme of immunization, sample collection, and challenge.
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2.9. Lymphocyte proliferation response
To detect changes in cellular immunity, lymphocyte proliferation response was performed.
Thymus and bursa of Fabricius were collected from immunized chickens at 7 and 21 days after
the first immunization. The thymus and BF lymphocytes were isolated and maintained in 1640
medium supplemented with 10% FBS at 37°C with 5% CO2. The thymus lymphocytes (5 × 106
cells/mL) were seeded in a 96-well plate and incubated with 50 μL of ConA (40 μg/mL) at 40°C/
5% CO2 for 48 h, whereas the BF lymphocytes (5 × 106 cells/mL) were treated with 50 μL of
PMA (1 μg/mL) in a 96-well plate at 40°C/5% CO2 for 24 h. Then, the lymphocyte proliferation
assay was performed using a standard MTT method as described previously [36, 37]. Then,
the plate was incubated with 10 μL of 5 mg/mL MTT for 3 h. Finally, 100 μL of 10% (w/v) SDS
in 0.01 M HCl was added into the plate and allowed to incubate for 2 h. A spectrophotometric
measurement was taken at A570.
2.10. Virus challenge experiment
Two weeks after the second vaccination, chickens (n = 15 per group) were intranasally
challenged with 2.5 × 106 TCID50 avian influenza virus A/chicken/Jiangsu/JS-1/2002(H9N2) in
100 μL PBS. Five chickens per group were humanely sacrificed at 3, 5, and 7 days after virus
challenge and the viral titers in their lungs assessed by plaque formation assays using MDCK
cells as described [35].
2.11. Statistical analysis
Statistical analyses were performed using unpaired t-tests or one-way analysis of variance
(ANOVA) F-statistics followed by GraphPad Prism 6 software. Data are presented as the mean
± standard deviation (SD). Turkey multiple comparison tests were used to assess differences
among the five experimental groups, with differences being considered significant at P < 0.05
or P < 0.01.
3. Results
3.1. Expression of the recombinant fusion peptide Tα1-BP5
The gene of Tα1-BP5 was amplified by SOE-PCR with the primers F1, F2, and F3. The PCR
products were identified by electrophoresis, and then about 114bp strip was observed. The
recombinant plasmid was extracted and identified with Hind III enzyme. The results showed
that the recombinant plasmid was not digested by Hind III, indicating that the recombinant
plasmid had deleted the Hind III restriction site (Figure 2A). Sequencing result showed that
the gene of the recombinant fusion peptide Tα1-BP5 was inserted into pET32a vector, and it
was consistent to the expected size (Table 3), which was suggested that the recombinant
expression vector was constructed successfully, and it was named pET32a-Tα1-BP5. Then,
pET32a-Tα1-BP5 was transferred into E. coli BL21 (DE3) for its expression, and the expressed
products were detected by using SDS-PAGE. The result showed that Tα1-BP5 was expressed
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and purified with the molecular weight of 31.4 kDa (Figure 2B), which is consistent with its
predicted molecular weight.
Name Amino acid sequence
Tα
1-BP5
Ser Asp Ala Ala Val Asp Thr Ser Ser Glu Ile Thr Thr Lys Asp Leu Lys Glu Lys Lys Glu Val Val Glu Glu Ala Glu
Asn Gly Gly Gly Gly Ser Cys Lys Asp Val Tyr
Table 3. Amino acid sequence of recombinant fusion peptide Tα1-BP5.
Figure 2. Identification of the recombinant plasmid pET32a-Tα1-BP5 and the expression of fusion peptide Tα1-BP5 in
E. coli. (A) 1: DL2000 marker; 2: the recombinant plasmid pET32a-Tα1-BP5 after Hind III enzyme digestion; and 3: the
recombinant plasmid pET32a-Tα1-BP5. (B) 1: low molecular weight protein marker; 2: not induced E. coli BL21 (DE3);
3: Not induced recombinant E. coli BL21 (DE3)/pET32a-Tα1-BP5; 4: induced recombinant E. coli BL21 (DE3)/pET32a-
Tα1-BP5.
3.2. Activity of rTα1-BP5 in vitro
The expressed product of TBP5 recombinant bacteria was affinity chromatography purified
through protein Ni column and quantified through spectrophotometer. MTT method was used
to test the effect of rTα1-BP5 on the proliferation of mouse thymic and splenic lymphocytes.
The results showed that all rTα1-BP5 with different concentrations (1.25, 2.5, 5.0, 10.0, and 20.0
μg/mL) could promote the proliferation of thymic and splenic lymphocytes compared to PBS
group. rTα1-BP5 could stimulate thymic and splenic lymphocytes proliferation stronger than
TP5 and BP5. The differences were significant (P < 0.05) on the concentrations of 5.0 and 20.0
μg/mL, and the differences were more significant (P < 0.01) on the concentrations of 10.0
μg/mL (Figure 3A and B). All these data demonstrated that rTα1-BP5 could promote the
proliferation of mouse thymic T lymphocytes and splenic B lymphocytes.
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Figure 3. The effects of rTα1-BP5 on the proliferation of thymic lymphocytes (A) or splenic lymphocytes (B) from im-
munized mice. The data presented are of five replicates. *, P < 0.05, compared with mice immunized with PBS, and **,
P < 0.01, compared with mice immunized with BP5 or Tα1.
Figure 4. Effect of rTα1-BP5 to H9N2 AIV vaccination on antigen-specific HI titers and anti-HA IgG antibodies. Chick-
ens were immunized two times, and chicken sera were collected on days 7 and 21 after the first immunization, and the
serum HI titers (A) and IgG titers (B) were analyzed by HI assay and ELISA, respectively. The data presented are
means ± SD of results from five replicates. *, P < 0.05, and **, P < 0.01, compared with chickens immunized with H9N2
WIV alone.
3.3. rTα1-BP5 stimulates significant antigen-specific immune responses
To determine antigen-specific immune responses to immunization, chickens were immunized
two times, then sera were taken on days 7 and 21 after the first immunization and detected for
HI and anti-HA antibody titers. HI antibody titers of chickens immunized with inactivated
vaccine, Tα1 combined with H9N2 WIV and BP5 combined with H9N2 WIV increased
significantly compared with chickens immunized with the H9N2 WIV alone at days 7 and 21
(P < 0.05). However, HI antibody titers in chickens immunized with rTα1-BP5 combined with
H9N2 WIV were significantly higher than in chicken immunized with BP5 combined with
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H9N2 WIV at days 7 and 21 (P < 0.05) (Figure 4A). Anti-HA IgG antibody was observed in
immunized chickens on days 7 and 21 after the first immunization. rTα1-BP5 enhanced the
secretion of IgG antibody on day 7 after the first immunization, and the effect was greater than
that induced by H9N2 AIV vaccine, Tα1 combined with H9N2 WIV and BP5 combined with
H9N2 WIV. On day 21 after the first immunization, BP5 significantly enhanced IgG antibody
secretion levels compared with that induced by H9N2 vaccine, Tα1 combined with H9N2 WIV
(P < 0.05), while the effect of rTα1-BP5 was the greatest than the other groups (P < 0.01) (Figure
4B). These results suggested that rTα1-BP5 stimulates significant antigen-specific immune
responses.
3.4. rTα1-BP5 promoted the production of AIV-neutralizing antibody
To assess whether rTα1-BP5 can effectively enhance virus-neutralizing antibodies, chicken sera
were collected on days 7 and 21 after the first immunization and the titers of AIV-neutralizing
antibody were assessed. The result showed that the titers of neutralizing antibody of chickens
immunized with Tα1 plus H9N2 WIV, BP5 plus H9N2 WIV, and H9N2 AIV vaccine were higher
than that in chickens immunized with H9N2 WIV alone on day 7, while it was higher in
chickens immunized with Tα1-BP5 plus H9N2 WIV than that of other groups. Consistent with
this, AIV-neutralizing antibody titers of chicken injected with rTα1-BP5 plus H9N2 WIV were
the highest on day 21 (Table 4). These results indicated that rTα1-BP5 significantly stimulates
the production of AIV-neutralizing antibodies.
Treatment PRNT50a
First boost Second boost
PBS – –
H9N2 WIV 10 ± 0.38 19 ± 0.21
H9N2 WIV + Tα1 15 ± 0.30* 22 ± 0.25*
H9N2 WIV + BP5 18 ± 0.32* 28 ± 0.43*
H9N2 WIV + rTα1-BP5 22 ± 0.24** 32 ± 0.19**
Inactivated H9N2 AIV vaccine 16 ± 0.15* 25 ± 0.54**
a Chickens were vaccinated on days 0 (first boost) and 14 (second boost). Chicken sera (n = 5) were collected on days 7
and 21, and plaque-reducing neutralizing antibody titers were determined. The 50% plaque-reducing neutralizing titer
(PRNT50) was reported as the geometrical reciprocal of the serum dilution resulting in a 50% reduction in plaques. The
data presented are means ± SD of results from five replicates.
*, P < 0.05, and
**, P < 0.01, compared with chickens immunized with H9N2 WIV alone.
Table 4. Titers of plaque-reducing neutralizing antibody in groups of chicken.
3.5. rTα1-BP5 increases the production of both Th1- and Th2-type cytokines
We then examined the levels of Th1 (IFN-γ) and Th2 (IL-4) cytokines from immunized
chickens. Compared with stimulation with H9N2 WIV alone, both IFN-γ and IL-4 secretion
were remarkably increased after immunization with inactivated H9N2 AIV vaccine, Tα1 plus
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H9N2 WIV and BP5 plus H9N2 WIV at days 7 and 21, and the highest level of IFN-γ secretion
was observed in the vaccination group with rTα1-BP5 plus H9N2 WIV (P < 0.01) (Figure 5A
and B). Taken together, the results suggested that rTα1-BP5 promoted the secretion of both
Th1 and Th2 cytokines.
Figure 5. Effect of rTα1-BP5 to H9N2 AIV vaccination on cytokine production in chicken sera. Chickens were immu-
nized two times, and chicken sera were collected on days 7 and 21 after the first immunization. Cytokine release was
measured by using commercial chicken cytokines gamma interferon (IFN-γ) and interleukin 4 (IL-4) ELISA kits. The
data presented are means ± SD of results from five replicates. *, P < 0.05, and **, P < 0.01, compared with chickens im-
munized with H9N2 WIV alone.
Figure 6. rTα1-BP5 significantly stimulates chicken T- and B-lymphocyte proliferation. Chickens were immunized two
times, and chicken thymus and bursa of Fabricius were collected on days 7 and 21 after the first immunization. T- (A)
and B (B)-lymphocyte proliferation assays were evaluated by MTT method. The data presented are means ± SD of re-
sults from five replicates. *, P < 0.05, and **, P < 0.01, compared with chickens immunized with H9N2 WIV alone.
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3.6. rTα1-BP5 significantly enhances T- and B-lymphocyte proliferation
To investigate the effects of rTα1-BP5 on T- and B-lymphocyte proliferation, thymus and BF
were collected from chickens immunized with rTα1-BP5 plus H9N2 WIV. T-lymphocyte
proliferation responses of chickens immunized with Tα1 plus H9N2 WIV, BP5 plus H9N2 WIV,
and H9N2 AIV vaccine were enhanced at 7 days compared with chickens immunized with
H9N2 WIV alone (P < 0.05), whereas it was higher for that immunized with rTα1-BP5 plus
H9N2 WIV (P < 0.01). On day 21, T-lymphocyte proliferation responses of chickens immunized
with Tα1 plus H9N2 WIV and H9N2 AIV vaccine were higher than chickens immunized with
H9N2 WIV alone (P < 0.05), while it was highest for that immunized with rTα1-BP5 plus H9N2
WIV (P < 0.01) (Figure 6A). Similarly, B-lymphocyte proliferation responses of chickens
immunized with BP5 plus H9N2 WIV and H9N2 AIV vaccine were enhanced at 7 and 21 days
compared with chickens immunized with H9N2 WIV alone (P < 0.05), whereas, it was highest
for that immunized with rTα1-BP5 plus H9N2 WIV (P < 0.01) (Figure 6B). The data indicated
that rTα1-BP5 promoted T- and B-lymphocyte proliferative responses.
3.7. rTα1-BP5 significantly promotes immune protection against H9N2 AIV challenge
To evaluate whether rTα1-BP5 promotes immune protection against H9N2 AIV infection, viral
titers in chicken lungs were evaluated at 3, 5, and 7 days after viral challenge by plaque
formation assays. Chickens immunized with Tα1 plus H9N2 WIV, BP5 plus H9N2 WIV, and
H9N2 AIV vaccine showed significant virus removal from the lungs at 3, 5, and 7 days after
challenge compared with H9N2 WIV groups (P < 0.05), while the viral titers of lungs from
chicken immunized with rTα1-BP5 plus H9N2 WIV were significantly lower than that in the
H9N2 AIV vaccine group (P < 0.01). Moreover, chickens immunized with rTα1-BP5 plus H9N2
WIV had almost no detectable virus particles in the lungs 7 days after challenge (Figure 7A–
C). The data indicated that rTα1-BP5 significantly promoted immune protection against H9N2
AIV challenge.
Figure 7. AIV-viral titers of lung in chickens. Lung samples from individual chicken in each group (n = 5) were collect-
ed on days 3, 5, and 7 post challenge with 2.5 × 106 TCID50 avian influenza virus (A/chicken/Jiangsu/JS-1/2002(H9N2)).
Each lung sample was diluted to 1 mL with 1640 media. The titers are presented as pfu per mL. The data presented are
means ± SD of results from five replicates. *, P < 0.05, and **, P < 0.01, compared with chickens immunized with H9N2
WIV alone.
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4. Discussion
In the event of an influenza pandemic, vaccination is one of the most effective ways of
intervention in terms of reducing cost, disease, and even death. Appropriate adjuvant can
enhance the immunogenicity of the vaccine and improve the immune responses [38, 39].
However, most of the adjuvants used in conjugation with antigen have unacceptable levels of
side effects, only a few of them are used clinically [40]. Thus, we need to find new and optimal
adjuvant candidates for vaccine. In recent years, some small peptide immunostimulants were
reported in use for vaccine adjuvants [41–43]. Both Tα1 and BP5 are associated with immune
regulation. Previous studies showed that both Tα1 and BP5 had high potential as an adjuvant
for vaccines [26, 44].
In this study, the fusion peptide of rTα1-BP5 was designed and synthesized, and to investigate
it as an adjuvant for inducing immune responses in chickens upon vaccination with inactivated
H9N2 avian influenza virus (WIV). An effective adjuvant should be able to enhance the levels
of both humoral and cell-mediated immunity. To investigate the effect of rTα1-BP5 on humoral
responses, chickens were immunized with H9N2 WIV combined with Tα1-BP5, and then titers
of HI antibody, antigen-specific antibodies, and AIV-neutralizing antibodies were assessed.
Then, we found that rTα1-BP5 significantly enhanced HI antibody and antigen-specific IgG
antibodies titers, promoted the secretion of AIV-neutralizing antibodies, which suggested that
rTα1-BP5 enhanced the levels of humoral immune responses in chickens when it was co-
immunized with H9N2 WIV.
In addition to humoral immune responses, cellular immunity also plays an important role in
fighting influenza virus infections [45]. The levels of Th1- and Th2-type cytokines are important
references to measure cellular immunity. And lymphocyte homeostasis is required for the
maintenance of normal immune function [46]. Th1-type cytokines mainly include IL-2, TNF-
α, and IFN-γ, whereas Th2-type cytokines include IL-4, IL-5, and IL-10 [47]. Our study though
analyzed the production of Th1 (IFN-γ)- and Th2 (IL-4)-type cytokines, and T- and B-lympho-
cytes proliferation in vaccinated chickens post immunization to evaluate the cell-mediated
immunity. The results suggested that rTα1-BP5 promoted the secretion of both Th1 and Th2
cytokines and T- and B-lymphocyte proliferative responses. Overall, this study found that
rTα1-BP5 not only enhanced the humoral immune responses but also promoted the cell-
mediated immune responses, and it had the potential to use as an adjuvant.
To further evaluate the influence of rTα1-BP5 as an adjuvant on the immunity protection
provided by H9N2 AIV vaccine against AIV infection, chickens were intramuscularly chal-
lenged with H9N2 AIV (A/chicken/Jiangsu/JS-1/2002) on day 28 post immunization. After 3
days post challenge, the PBS group chickens that received the challenge virus were mildly
depressed. No other clinical signs were observed in that group or any of the other groups,
which is typical of low-pathogenicity AIV in chickens [48, 49]. At 7 days post challenge, only
the PBS-challenged group had mild, grossly detectable lesions in both the respiratory and
gastrointestinal tract. And we found that the viral titers of lungs from chicken immunized with
rTα1-BP5 plus H9N2 WIV were significantly lower than all the other groups at 3 days. Chickens
immunized with rTα1-BP5 plus H9N2 WIV had almost no detectable virus particles in the
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lungs at 7 days after challenge. Our data indicated that rTα1-BP5 could effectively inhibit the
replication of H9N2 AIV in chickens and promote virus clearance in the lungs of chickens.
Thus, rTα1-BP5 had the potential to be used in vaccine formulations to provide improved
protection against H9N2 AIV infection in poultry.
In summary, this study demonstrated that inactivated H9N2 AIV vaccine with Tα1-BP5 as an
adjuvant enhanced strong immune responses at both humoral and cellular levels against AIV
infection in chickens. These data may provide a novel insight to find new adjuvant in vaccines.
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